Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story - Summary - MDSpire

Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story

  • By

  • Sana Raoof

  • June 4, 2026

  • 0 min

Share

Objective:

To evaluate the effectiveness of the Galleri multi-cancer early detection (MCED) test in reducing stage 3 and 4 cancers in a randomized trial.

Key Findings:
  • The positive predictive value (PPV) of the Grail test was 52%, higher than many existing screening tests.
  • The trial revealed a paradoxical increase in stage 3 cancers alongside a decrease in stage 4 cancers, negating the primary endpoint.
  • Grail's testing quadrupled the number of screen-detected cancers, which are generally associated with better outcomes.
Interpretation:

Limitations:
  • The trial duration of three years may have been insufficient to observe significant outcomes.
  • The primary endpoint may not have adequately captured the potential for curative treatments.
Conclusion:

Original Source(s)

Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story

  • by Sana Raoof

  • June 4, 2026

Related Content

Preliminary construction and validation of a prognostic prediction model for cervical cancer based on tumor mechanics-related genes

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib